CTO Realty Growth (NYSE:CTO) ("CTO" or the "Company") today announced the launch of a public offering of shares of its Series A Cumulative Redeemable Preferred Stock (the "Series A Preferred
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in Alzheimer’s disease.
Synchronoss Technologies, Inc. (SNCR) (the "Company" or "Synchronoss"), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that the Company intends